Funding for this research was provided by:
Text and Data Mining valid from 2018-06-22
Received: 9 April 2018
Accepted: 10 May 2018
First Online: 22 June 2018
Ethics approval and consent to participate
: The COOL trial has been ethically approved at the lead and pilot center by the Conjoint Health Research Ethics Board (CHREB) of the University of Calgary (REB16-1588). The study has also been registered with the National Institutes of Health (ExternalRef removed, identifier: NCT03163095).
: Andrew W. Kirkpatrick serves in the Canadian Forces Medical Services and has consulted for the Innovative Trauma Care and Acelity Corporations. Jessica L. McKee declares that she has consulted for Innovative Trauma Care, Aceso, and the Acelity Corporations. Osvaldo Chiara reported having consulted for the Acelity Corporation. Jose J. Diaz reported having consulted for the Acelity Corporation. Michael Sugrue reported having consulted for the Smith and Nephew Corporation. Ernest E. Moore reported Research support and intellectual property related to the Haemonetics, TEM Systems, Pryor Corporations, and being a Cofounder of Thrombo Therapeutics Inc. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.